DURECT CORP. overview

DURECT Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update PR Newswire CUPERTINO, Calif., March 27, 2024 - Ongoing Communication with FDA to Align on Next Steps for Larsucosterol in Alcohol-Associated Hepatitis - Webcast of Earnings Call Today, March 27th at 4:30 p.m. ET CUPERTINO, Calif. , March 27, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the fourth quarter and year ended December 31, 2023 and...

DURECT Corporation to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update PR Newswire CUPERTINO, Calif., March 20, 2024 CUPERTINO, Calif. , March 20, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer, today announced that the company will report its...

DURECT and Charles River Laboratories Enter into Co-Marketing and Collaboration Agreement for ALZET® Product Line in U.S. and Canada PR Newswire CUPERTINO, Calif., March 4, 2024 Partnership agreement will be the first-ever co-marketing and sales collaboration for the ALZET Osmotic Pumps Portfolio and Associated Product Line in the U.S. and Canada Both companies will jointly market and commercialize the ALZET product line to customers over a multi-year period CUPERTINO, Calif. , March 4, 2024...

DURECT Corporation to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference PR Newswire CUPERTINO, Calif., Feb. 7, 2024 CUPERTINO, Calif. , Feb. 7, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that James E. Brown , President and Chief Executive Officer, will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference, to be held virtually, February 13-14, 2024 . Presentation details are as follows: Date and Time: Wednesday, February...

DURECT Corporation Reports Third Quarter 2023 Financial Results and Business Update PR Newswire CUPERTINO, Calif., Nov. 13, 2023 - Webcast of Earnings Call Today, November 13th at 4:30 p.m. ET - Topline data from AHFIRM trial showed compelling efficacy signal in favor of larsucosterol in the key secondary endpoint of mortality at 90 days CUPERTINO, Calif. , Nov. 13, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended September 30,...

DURECT Corporation to Announce Third Quarter 2023 Financial Results and Provide a Business Update PR Newswire CUPERTINO, Calif., Nov. 9, 2023 CUPERTINO, Calif. , Nov. 9, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer, today announced that the company will report its financial results for...

DURECT Corporation Announces Topline Results from Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis with Promising Effect on Mortality PR Newswire CUPERTINO, Calif., Nov. 7, 2023 Compelling efficacy signal in favor of larsucosterol in the key secondary endpoint of mortality at 90 days. Clinically relevant reduction in 90-day mortality of 41% for 30 mg dose and 35% for 90 mg dose compared with standard of care (SOC) Numerical improvement in primary endpoint of mortality or...

DURECT Corporation Announces Last Patient Last Visit in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis PR Newswire CUPERTINO, Calif., Sept. 7, 2023 Company on track to report topline data from AHFIRM in Q4 2023 CUPERTINO, Calif. , Sept. 7, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions, including acute...